Literature DB >> 19733666

Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.

Xavier Xifró1, Albert Giralt, Ana Saavedra, Juan M García-Martínez, Miguel Díaz-Hernández, José J Lucas, Jordi Alberch, Esther Pérez-Navarro.   

Abstract

Calcineurin is a serine/threonine phosphatase involved in the regulation of glutamate receptors signaling. Here, we analyzed whether the regulation of calcineurin protein levels and activity modulates the susceptibility of striatal neurons to excitotoxicity in R6/1 and R6/1:BDNF+/- mouse models of Huntington's disease. We show that calcineurin inhibition in wild-type mice drastically reduced quinolinic acid-induced striatal cell death. Moreover, calcineurin A and B were differentially regulated during disease progression with a specific reduction of calcineurin A protein levels and calcineurin activity at the onset of the disease in R6/1:BDNF+/- mice. Analysis of the conditional mouse model Tet/HD94 showed that mutant huntingtin specifically controls calcineurin A protein levels. Finally, calcineurin activation induced by intrastriatal quinolinic acid injection in R6/1 mouse was lower than in wild-type mice. Therefore, reduction of calcineurin activity by alteration of calcineurin A expression participates in the pathophysiology of Huntington's disease and contributes to the excitotoxic resistance observed in exon-1 mouse models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733666     DOI: 10.1016/j.nbd.2009.08.012

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  11 in total

1.  Striatal-enriched protein tyrosine phosphatase expression and activity in Huntington's disease: a STEP in the resistance to excitotoxicity.

Authors:  Ana Saavedra; Albert Giralt; Laura Rué; Xavier Xifró; Jian Xu; Zaira Ortega; José J Lucas; Paul J Lombroso; Jordi Alberch; Esther Pérez-Navarro
Journal:  J Neurosci       Date:  2011-06-01       Impact factor: 6.167

Review 2.  Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.

Authors:  Michelle E Ehrlich
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

3.  Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.

Authors:  N Cabezas-Llobet; L Vidal-Sancho; M Masana; A Fournier; J Alberch; D Vaudry; X Xifró
Journal:  Mol Neurobiol       Date:  2018-03-10       Impact factor: 5.590

Review 4.  Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

Authors:  L A Raymond; V M André; C Cepeda; C M Gladding; A J Milnerwood; M S Levine
Journal:  Neuroscience       Date:  2011-08-27       Impact factor: 3.590

Review 5.  Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders.

Authors:  Susan M Goebel-Goody; Matthew Baum; Constantinos D Paspalas; Stephanie M Fernandez; Niki C Carty; Pradeep Kurup; Paul J Lombroso
Journal:  Pharmacol Rev       Date:  2011-11-16       Impact factor: 25.468

6.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

7.  Early down-regulation of PKCδ as a pro-survival mechanism in Huntington's disease.

Authors:  Laura Rué; Rafael Alcalá-Vida; Graciela López-Soop; Jordi Creus-Muncunill; Jordi Alberch; Esther Pérez-Navarro
Journal:  Neuromolecular Med       Date:  2013-07-30       Impact factor: 3.843

8.  The Role of Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Cognition.

Authors:  Christopher James Fitzpatrick; Paul J Lombroso
Journal:  Front Neuroanat       Date:  2011-07-29       Impact factor: 3.856

9.  Altered Regulation of Striatal Neuronal N-Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model.

Authors:  Rujun Kang; Liang Wang; Shaun S Sanders; Kurt Zuo; Michael R Hayden; Lynn A Raymond
Journal:  Front Synaptic Neurosci       Date:  2019-02-21

Review 10.  Possible involvement of self-defense mechanisms in the preferential vulnerability of the striatum in Huntington's disease.

Authors:  Laetitia Francelle; Laurie Galvan; Emmanuel Brouillet
Journal:  Front Cell Neurosci       Date:  2014-09-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.